

Curriculum Vitae

Full Name: Se-Hoon Lee

Position Title: Professor

Address: Division of Hematology/Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
81 Irwon-Ro, Gangnam-gu,
Seoul, 135-710, South Korea

Education:

Institution and Location	Degree	Year Conferred	Field of Study
College of Medicine, Seoul National University Seoul, Korea	M.D.	1996	Medicine
Graduate School, Seoul National University, Seoul, Korea	M.S.	2001	Medicine
Graduate School, Seoul National University, Seoul, Korea	Ph.D.	2008	Medicine
Seoul National University Hospital, Seoul, Korea	Internship & Residency	2001	Dept. of Internal Medicine
Seoul National University Hospital, Seoul, Korea	Fellowship	2002	Section of Hematology/Medical Oncology, Dept. of Internal Medicine
Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Fellowship	2004	Division of Hematology & Medical Oncology, Dept. of Medicine

Research and Professional Experience:

Position	Institution/Employer and Location	Dates of Employment
Professor	Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	Mar, 2015~
Visiting Scholar	Dana-Farber Cancer Institute, Boston, MA (Harvard Medical School) Broad Institute, Cambridge, MA	Jul, 2009~Jan, 2011
Assistant & Associate Professor	Seoul National University Hospital, Seoul National University College of Medicine	Apr, 2005~Feb, 2015
Clinical Instructor	Samsung Medical Center, Seoul, Korea	Apr, 2004~Mar, 2005
Research Fellow	Samsung Medical Center	Mar, 2004~Apr, 2004
Clinical Fellow	Samsung Medical Center	Mar, 2002~Feb, 2004
Clinical Fellow	Seoul National University Hospital	May, 2001~Feb, 2002

Professional Memberships:

The Korean Association of Internal Medicine	2001
Korean Cancer Association	2001
American Society of Clinical Oncology (ASCO)	2003
Korean Cancer Study Group, GU section	2003
Korean Association for Clinical Oncology	2006

International Association for the Study of Lung Cancer (IASLC)	2007
American Association for Cancer Research (AACR)	2007
Korean Urological Oncology Society	2008
Korean Society of Neuro-Oncology	2011
Society of Neuro-Oncology (SNO)	2011
Korean Genome Organization	2012

**Relevant Clinical Trial Experience:
(since 2011)**

Phase I/II study of EGFR TKI in NSCLC as an investigator in 2014
Phase III study of PD-1 target agent vs cytotoxics in NSCLC as an investigator in 2014
Phase II (proof-of-concept) study of TKI in NSCLC as a principal investigator in 2013 (IST)
Phase I study of TKI in NSCLC as an investigator in 2011
Phase II study of TKI in NSCLC second-line as an investigator in 2011
Phase III study of TKI in NSCLC first-line as an investigator in 2011
Phase III study of pan-Her inhibitor in NSCLC first-line as an investigator in 2011
Phase II study of Hsp90 inhibitor in NSCLC second-line as an investigator in 2011
Phase II study of PI3K inhibitor in NSCLC second-line as an investigator in 2011

Phase I/II study of EGFR-mAb and PI3K inhibitor in HNSCC as a principal investigator in 2013
Phase II study of cytotoxic combination in HNSCC as a principal investigator in 2012 (IST)
Phase II study of ERGFR inhibitor in HNSCC as a principal investigator in 2012 (IST)
Phase I/II study of EGFR-mAb and TKI in HNSCC as an investigator in 2011
Phase I/II study of TKI in HNSCC as an investigator in 2011

Phase I/II study of PI3K inhibitor and Her3 monoclonal antibody in esophageal cancer a principal investigator in 2013
Phase II study of EGFR inhibitor in esophageal cancer a principal investigator in 2013 (IST)

Phase II study of cytotoxic combination in recurrent glioblastoma as a principal investigator in 2013 (IST)
Phase II study of cytotoxic combination in recurrent anaplastic oligodendroglioma as a principal investigator in 2013 (IST)
Phase II study of cytotoxic combination in recurrent glioblastoma as a principal investigator in 2012 (IST)
Phase II study of cytotoxic in anaplastic glioma as a principal investigator in 2012 (IST)

Phase I study of PD-1 mAb as an investigator in 2014
Phase I study of PD-L1 mAb an investigator in 2014
Phase I study of Her2 mAb as an investigator in 2013
Phase I study of TKI in solid tumors as an investigator in 2011
Phase I study c-met-TKI in solid tumors as an investigator in 2011
Phase I study pan-Her inhibitor in solid tumors as an investigator in 2011
Phase I study of Her2 mAb in solid tumors as an investigator in 2011

I participated in the clinical trials described above and additional ones not described. GCP training was done at the investigator meeting more than 50 times till now.

I hearby certify that this document is an accurate representation of my qualifications.